Myotonic dystrophy
Drug research and approvals for myotonic dystrophy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 40 studies of myotonic dystrophy are recruiting on ClinicalTrials.gov, Health Canada has authorized 13 drug trials for it since 2013, and FDA has 0 approved and 11 open orphan designations naming it.
- Recruiting worldwide: 40
- Trials authorized in Canada: 13
- FDA orphan approvals: 0
- EU medicines: 0
- Metabolomic Biomarkers of Myotonic DystrophyNCT07912983 · Not reported · Massachusetts General Hospital · starts Oct 26, 2026
- Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) ExtensionNCT07700225 · Not reported · Virginia Commonwealth University · starts Oct 15, 2026
- Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic DystrophyNCT07630389 · Not reported · University of Rochester · starts Nov 13, 2023
- Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in…NCT07608432 · Phase 3 · Dyne Therapeutics · starts Jun 1, 2026
- A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in…NCT07587242 · Phase 3 · Avidity Biosciences, Inc. · starts Sep 1, 2026
- VirtualPark_PediatricNCT07580365 · Not applicable · Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato · starts Jun 30, 2026
- Remote Assessments and Genetic Determinants of Myotonic DystrophyNCT07505342 · Not reported · University of Rochester · starts May 10, 2022
- Muscle Health Measurements Using Electrical Impedance MyographyNCT07502989 · Not reported · Beth Israel Deaconess Medical Center · starts Apr 9, 2025
- Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1NCT07486934 · Phase 3 · Dyne Therapeutics · starts May 14, 2026
Phase 3 1
- MexiletineSodium channel alpha subunit blocker
Phase 2 3
- TideglusibGlycogen synthase kinase-3 beta inhibitor
- Prasterone
- Mecasermin rinfabateInsulin-like growth factor I receptor agonist
How its trials ended
100 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 12 whose ending is known, 50% met their primary endpoint, 8% missed it and 42% stopped early.
- Ongoing4242%
- Completed, result not reported3636%
- Status unknown1010%
- Met its primary endpoint66%
- Stopped: other or unclear55%
- Missed its primary endpoint11%
| Jan 14, 2026 | A phase 1, open-label trial to assess the safety and pharmacokinetics of multiple ascending doses of DT-818 in healthy volunteers and participants with…DT-818 | Design Therapeutics | Ongoing |
| Aug 28, 2025 | A global phase 3 open-label extension study to assess the long-term safety, tolerability, and efficacy of intravenous aoc 1001 for the treatment of myotonic…Aoc 1001 (AV01MAB-MD01-DS001) | Avidity Biosciences | Ongoing |
| Jul 11, 2025 | A phase 1/phase 2 open-label single arm study with dose escalation (part a), and dose expansion (part b) parts to evaluate the safety, tolerability, and…SAR446268 | Sanofi-Aventis Canada Inc | Ongoing |
| Jul 8, 2025 | An open-label extension study evaluating safety and pharmacokinetics in participants with myotonic dystrophy type 1 (freedom-ole)PGN-EDODM1 | PepGen | Ongoing |
| Jun 28, 2024 | A phase 3 randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of intravenous aoc 1001 for the treatment of myotonic…Aoc 1001 (AV01MAB-MD01-DS001) | Avidity Biosciences | Closed |
| May 17, 2024 | A phase 2 randomized, double-blind, placebo-controlled, multiple-ascending dose study of pgn-EDODM1 in adult participants with myotonic dystrophy type 1…PGN-EDODM1 | PepGen | Ongoing |
| Apr 12, 2024 | A phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-DM1 (SRP-1003) in subjects with type 1…SRP-1003 (ARO-DM1, ADS-019) | Sarepta Therapeutics | Ongoing |
| Mar 14, 2024 | A phase 1/2a double-blind, placebo-controlled, single- and multiple ascending dose study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics…ATX-01 (X82108) | Arthex Biotech, S.L. | Ongoing |
| Nov 2, 2023 | A phase 1/2, randomized, double-blind, placebo¿controlled single- and multiple¿dose escalation study evaluating the safety, tolerability, pharmacokinetics, and…VX-670 | Vertex Pharmaceuticals | Ongoing |
| Aug 18, 2023 | A phase 1 placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single-ascending doses of pgn-EDODM1 in adult…PGN-EDODM1 | PepGen | Closed |
| Oct 17, 2025 | An antibody-siRNA conjugate, comprised of a humanized…Treatment of myotonic dystrophy type 1 (DM1) | ChainGen Biopharma Ltd. | Designated |
| Jun 26, 2025 | MecaserminTreatment of myotonic dystrophy type 1 | Sarcomed AB | Designated |
| Sep 20, 2024 | A phosphorodiamidate morpholino oligomer consisting of 7…Treatment of Myotonic Dystrophy Type 1 | Vertex Pharmaceuticals Incorporated | Designated |
| Jul 10, 2024 | A nonreplicating adeno-associated virus, serotype SAN011…Treatment of myotonic dystrophy type 1 | Sanofi US Services Inc. | Designated |
| Nov 27, 2023 | Recombinant fusion protein (biologic) made by linking human…Treatment of myotonic dystrophy type 1 | Juvena Therapeutics, Inc. | Designated |
| Sep 19, 2023 | Human transferrin 1 receptor (TfR1) targeting humanized IgG…Treatment of Myotonic Dystrophy Type I | Dyne Therapeutics, Inc. | Designated |
| Aug 1, 2023 | A synthetic peptide-oligonucleotide conjugate in which a…Treatment of Myotonic Dystrophy type 1 (also known as Steinert disease) | PepGen Inc. | Designated |
| May 10, 2022 | A lyophilized modified oligonucleotide of 16 nucleotides…Treatment of myotonic dystrophy type 1 (DM1) | Arthex Biotech S.L. | Designated |
| Jul 21, 2021 | An antibody oligonucleotide conjugate (AOC), comprised of a…Treatment of Myotonic Dystrophy Type 1 (DM1) | Avidity Biosciences | Designated |
| Jun 19, 2017 | TideglusibTreatment of myotonic dystrophy type 1 (DM1) | AMO Pharma Ltd. | Designated |
| Dec 3, 2007 | MecaserminTreatment of myotonic dystrophy | Insmed, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA